N-[[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide sodium salt; CRID3; CP-456773 sodium salt
256373-96-3
426.5
C20H23N2O5S • Na
Water, DMSO
-20°C
MCC-950 was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1. Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes. Blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations. Inhibits interleukin 1β (IL-1β) secretion in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model). Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome. A valuable new tool for exploring the pathophysiology of NLRP3.
Research or further manufacturing use only, not for food or drug use.
